CLINICAL TRIALS PROFILE FOR DIASTAT
✉ Email this page to a colleague
All Clinical Trials for DIASTAT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00326612 ↗ | Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures | Completed | Primary Children's Hospital | Phase 2 | 2006-06-01 | The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions. |
| NCT00326612 ↗ | Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures | Completed | University of Utah | Phase 2 | 2006-06-01 | The investigators will conduct a randomized controlled trial comparing the use of nasal midazolam, using a Mucosal Atomization Devise, to rectal diazepam for the treatment of acute seizure activity in children under the age of 18 years with epilepsy in the community setting. The primary hypothesis is that nasal midazolam will be more effective and have shorter seizure time compared to rectal diazepam in the community. The secondary hypotheses are that patients treated with nasal midazolam will have fewer respiratory complications, emergency department visits, and admissions. |
| NCT01364558 ↗ | A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers | Completed | Neurelis, Inc. | Phase 1 | 2011-02-01 | The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration |
| NCT01364558 ↗ | A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers | Completed | University of Minnesota | Phase 1 | 2011-02-01 | The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration |
| NCT01364558 ↗ | A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers | Completed | University of Minnesota - Clinical and Translational Science Institute | Phase 1 | 2011-02-01 | The purpose of this clinical research study is to assess the bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and injectable diazepam after intravenous (I.V.) administration |
| NCT02474407 ↗ | Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) | Terminated | Acorda Therapeutics | Phase 2 | 2015-06-01 | This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat) |
| NCT02724423 ↗ | Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects | Completed | Neurelis, Inc. | Phase 1 | 2016-06-30 | This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will be based on the subject's body weight. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DIASTAT
Condition Name
Clinical Trial Locations for DIASTAT
Trials by Country
Clinical Trial Progress for DIASTAT
Clinical Trial Phase
Clinical Trial Sponsors for DIASTAT
Sponsor Name
